Reata Expands Options For Bardoxolone With New CKD Data
Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.
You may also be interested in...
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).